Dexamethasone for Cerebral Toxoplasmosis (De-Tox)
Toxoplasmosis, Cerebral
About this trial
This is an interventional treatment trial for Toxoplasmosis, Cerebral
Eligibility Criteria
Inclusion Criteria:
- Age 18 years or above.
- Clinical signs and symptoms compatible to cerebral toxoplasmosis
- Serology HIV positive
- Immunoglobulin G anti-toxoplasma titre is positive
- One or more mass lesions on the neuroradiological finding
- None or less than 3 days of dexamethasone therapy taken
- Written informed consent from the patients or from close relatives of the patient if the patient is unconscious.
Exclusion Criteria:
- History of anti-toxoplasmosis administrattion for more than 5 days before recruitment
- Hypersensitivity or other contraindication to dexamethasone
- Pregnancy
Sites / Locations
- Hasan Sadikin General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Dexamethasone
Placebo
Sixty nine patients will be administered randomly dexamethasone 20 mg IV for 7 days. Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines.
Sixty nine patients will be administered randomly Normal Saline 0,9% IV (4 cc) for 7 days. Along with study drug or placebo, patients will receive standard anti toxoplasmosis (Oral pyrimethamine 150 or 200 mg (according to body weight) for three days continued by 50 or 75mg (according to body weight) per day or oral cotrimoxazole 2 x 1920 mg; oral clindamycin 600mg q.i.d) in accordance to national neurologist association guidelines.